Reply to "Galantamine and QTc Prolongation"
J Clin Psychiatry 2007;68:169-170 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: We appreciate and read with interest the comments by Drs. Brashear and Spivey. In response to our case report,1 they presented unpublished data from 2 studies performed by Johnson & Johnson Pharmaceutical Research and Development: 1 in subjects with schizophrenia and 1 in subjects with Alzheimer’s disease. Because these studies are unpublished, we are unable to evaluate important study sample details, such as subject age and gender, comorbid diseases, and concomitant medications, and therefore cannot comment on the relevance of their results to the case that we presented.